Status:
UNKNOWN
Proteomics Study of Gastric Bypass Surgery to Treat Type 2 Diabetes Mellitus
Lead Sponsor:
No. 150 Central Hospital of the Chinese People Liberation Army
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18-65 years
Brief Summary
The purpose of this study is to reveal the key proteins involved in gastric bypassing surgery which may effect the decreased glucose in type 2 diabetes patietns, and evaluate standard remission rate a...
Detailed Description
Diabetes Mellitus is a major global problem which responsibles for 4.6 million deaths each year without effective therapy methods. Recently，researchers showed that type 2 diabetes mellitus can be part...
Eligibility Criteria
Inclusion
- patients diagnosed as type 2 diabetes are planning to have Roux-en-Y gastric bypass
- age:18-65yr
- HbAlc\>8%
Exclusion
- diabetes (applies for control patients)
- chronic inflammatory disease
- malignant disease
- pregnancy
- prior gastric, duodenal, proximal jejunal surgery or pancreas resection
- current use of thiazolidinediones
- treatment with incretin mimetics or DPP IV inhibitors in the prior 3 months
- HbAlc\<8%
- any condition felt by the investigator to interfere with ability to complete the study
Key Trial Info
Start Date :
October 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2013
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01870713
Start Date
October 1 2010
End Date
October 1 2013
Last Update
June 6 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
No. 150 Central hospital of Chinese People's Liberation Army
Luoyang, Henan, China, 471000